ALYREF, NSUN5, DNMT1 |
HNSCC |
Participate in progress and predict prognosis |
Involved in regulating tumor energy metabolism and protein synthesis |
[90] |
NSUN2 |
Gastric Cancer |
Cell Proliferation |
Regulate downstream gene p57Kip2 |
[98] |
NSUN2 |
HDFs |
Cell Proliferation and Senescence |
Regulate the expression of p27 and CDK1 |
[99] |
NSUN2 |
U87 |
Cell Migration |
Participate in regulation by methylating ATX mRNA |
[100] |
NSUN2 |
HCC |
Cell Differentiation |
Recruit oncoprotein G3BP1 |
[95] |
NSUN2, ALYREF |
Bladder Cancer |
Cell Proliferation and Migration |
Regulation of mRNA stability through a new binding protein YBX1 in the cytoplasm |
[31] |
NSUN6 |
Pancreatic Cancer |
Cell Proliferation |
Regulates cell cycle and G2M checkpoints |
[101] |
NSUN4, ALYREF |
HCC |
Tumor progression |
High expression of NSUN4 and ALYREF is significantly correlated with survival outcome |
[94] |
NSUN2, NSUN6 |
TNBC |
Tumor proliferation Occurrence and Metastasis. |
Affect tumor development and tumor immune microenvironment |
[102] |
NSUN2 |
Gastrointestinal Cancer |
Tumor progression and pathological staging |
Regulates GSK3B and participates in the ErbB/PI3K-Akt signaling pathway |
[103] |
DNMT3A |
Glioblastoma Multiforme |
Tumor progression |
Inhibit the formation of miRNA/mRNA duplexes, loss of tumor suppression kinetic energy |
[104] |
ALYREF |
Bladder Cancer |
Glycolysis and Tumorigenesis |
Overexpression of ALYREF promotes the proliferation of bladder cancer cells through PKM2-mediated glycolysis. |
[105] |